oxybutynin has been researched along with Asialia in 28 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis." | 9.20 | Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. ( Abasq-Thomas, C; Brenaut, E; Chassain-Le Lay, M; Dupré-Goetghebeur, D; Gouedard, C; Greco, M; Jouan, N; Le Gal, G; Le Ru, Y; Menard-Andivot, N; Misery, L; Penven, K; Pillette-Delarue, M; Roguedas-Contios, AM; Sassolas, B; Schollhammer, M; Zagnoli, A, 2015) |
| " In this post hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence (UUI) with focus on flexible dosing." | 9.14 | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. ( Bödeker, RH; Madersbacher, H; Neumeister, C; Zellner, M, 2010) |
| "This retrospective study analyzed 20 patients (10 females) who received oxybutynin for primary focal hyperhidrosis at uncommon sites." | 7.80 | Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin. ( Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "All patients treated with oxybutynin between February 2008 and October 2010 for troublesome generalized hyperhidrosis were recruited after ruling out underlying disease." | 7.77 | [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis]. ( Bara, C; Célérier, P; Fenot, M; Maillard, H, 2011) |
| " After an initial placebo run-in period, dosing in each began at 5 mg per day and increased weekly by 5 mg per day to a maximum of 20 mg per day or when a balance between improvement of incontinence symptoms and tolerability of side effects was achieved." | 6.69 | Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. ( Appell, R; Mobley, D; Patton, W; Saltzstein, D; Versi, E, 2000) |
| "To evaluate the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis." | 5.20 | Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. ( Abasq-Thomas, C; Brenaut, E; Chassain-Le Lay, M; Dupré-Goetghebeur, D; Gouedard, C; Greco, M; Jouan, N; Le Gal, G; Le Ru, Y; Menard-Andivot, N; Misery, L; Penven, K; Pillette-Delarue, M; Roguedas-Contios, AM; Sassolas, B; Schollhammer, M; Zagnoli, A, 2015) |
| " In this post hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence (UUI) with focus on flexible dosing." | 5.14 | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. ( Bödeker, RH; Madersbacher, H; Neumeister, C; Zellner, M, 2010) |
| "To assess the efficacy, incidence of dry mouth and overall satisfaction with initial doses of 5, 10 and 15 mg of a new, once-daily, controlled-release (CR) form of oxybutynin for treating urge urinary incontinence (UUI)." | 5.12 | A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. ( Andreou, C; Casey, R; Corcos, J; Darke, AC; Harsanyi, Z; Miceli, PC; Patrick, A; Reiz, JL, 2006) |
| "Oxybutynin is used for the treatment of urge urinary incontinence." | 5.09 | Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. ( Gupta, SK; Sathyan, G, 1999) |
| "This retrospective study analyzed 20 patients (10 females) who received oxybutynin for primary focal hyperhidrosis at uncommon sites." | 3.80 | Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin. ( Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "All patients treated with oxybutynin between February 2008 and October 2010 for troublesome generalized hyperhidrosis were recruited after ruling out underlying disease." | 3.77 | [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis]. ( Bara, C; Célérier, P; Fenot, M; Maillard, H, 2011) |
| "Byakko-ka-ninjin-to (BN) is a Kampo medicine (traditional Japanese medicine) that is frequently used to treat xerostomia, which is also a side effect of anticholinergic agents such as oxybutynin and propiverine widely used for the treatment of patients with urinary incontinence or frequency." | 3.73 | Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats. ( Aburada, M; Goto, K; Hattori, N; Ichiki, H; Iizuka, A; Ishige, A; Sakaguchi, M; Takeda, S; Yamamoto, M; Yamamoto, T; Yasuda, M, 2005) |
| " Peak plasma concentrations of oxybutynin and the major active metabolite, N-desethyloxybutynin, are reached 24 - 48 hours after a single application and therapeutic concentrations are maintained throughout the dosage interval." | 2.71 | Transdermal oxybutynin: for overactive bladder. ( Bang, LM; Easthope, SE; Perry, CM, 2003) |
| " The side effect profile (dry mouth) was comparable between tolterodine, 2 mg twice daily, and placebo, but differed significantly when comparing tolterodine SSD with oxybutynin SSD (P < 0." | 2.71 | Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. ( Bard, RJ; Casey, AR; Ethans, KD; Nance, PW; Schryvers, OI, 2004) |
| " After an initial placebo run-in period, dosing in each began at 5 mg per day and increased weekly by 5 mg per day to a maximum of 20 mg per day or when a balance between improvement of incontinence symptoms and tolerability of side effects was achieved." | 2.69 | Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. ( Appell, R; Mobley, D; Patton, W; Saltzstein, D; Versi, E, 2000) |
| "All medical records, including the Overactive Bladder Symptom score (OABSS), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score (IPSS) questionnaires, and uroflowmetry parameters were reviewed at each visit." | 1.48 | Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year. ( Hsiao, SM; Kuo, HC; Lin, HH, 2018) |
| " The majority of discontinuations were for adverse events; dry mouth was the most frequently cited event leading to discontinuation (8." | 1.31 | Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. ( Albrecht, D; Antoci, J; Atkinson, L; Diokno, A; Labasky, R; Leach, G; Sand, P; Sieber, P, 2002) |
| "Oxybutynin is an effective drug to stop detrusor hyperactivity, but it has a high rate of anticholinergic adverse reactions." | 1.30 | [Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder]. ( Arango Toro, O; Castro Santamaría, R; Cortadellas Angel, R; Gelabert Mas, A; Nohales Taurines, G, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 16 (57.14) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, RS | 1 |
| Rhodes, BH | 1 |
| Siewe, MS | 1 |
| Matthews, TJ | 1 |
| Teivelis, MP | 1 |
| Wolosker, N | 1 |
| Krutman, M | 1 |
| Kauffman, P | 1 |
| Campos, JR | 1 |
| Puech-Leão, P | 1 |
| Schollhammer, M | 1 |
| Brenaut, E | 1 |
| Menard-Andivot, N | 1 |
| Pillette-Delarue, M | 1 |
| Zagnoli, A | 1 |
| Chassain-Le Lay, M | 1 |
| Sassolas, B | 1 |
| Jouan, N | 1 |
| Le Ru, Y | 1 |
| Abasq-Thomas, C | 1 |
| Greco, M | 1 |
| Penven, K | 1 |
| Roguedas-Contios, AM | 1 |
| Dupré-Goetghebeur, D | 1 |
| Gouedard, C | 1 |
| Misery, L | 1 |
| Le Gal, G | 1 |
| Bostock, C | 1 |
| McDonald, C | 1 |
| Hsiao, SM | 1 |
| Lin, HH | 1 |
| Kuo, HC | 1 |
| Herschorn, S | 1 |
| Stothers, L | 1 |
| Carlson, K | 1 |
| Egerdie, B | 1 |
| Gajewski, JB | 1 |
| Pommerville, P | 1 |
| Schulz, J | 1 |
| Radomski, S | 1 |
| Drutz, H | 1 |
| Barkin, J | 1 |
| Paradiso-Hardy, F | 1 |
| Bödeker, RH | 1 |
| Madersbacher, H | 1 |
| Neumeister, C | 1 |
| Zellner, M | 1 |
| Maillard, H | 1 |
| Fenot, M | 1 |
| Bara, C | 1 |
| Célérier, P | 1 |
| Appell, RA | 2 |
| Diokno, A | 1 |
| Sand, P | 2 |
| Labasky, R | 1 |
| Sieber, P | 1 |
| Antoci, J | 1 |
| Leach, G | 1 |
| Atkinson, L | 1 |
| Albrecht, D | 2 |
| Bang, LM | 1 |
| Easthope, SE | 1 |
| Perry, CM | 1 |
| Ethans, KD | 1 |
| Nance, PW | 1 |
| Bard, RJ | 1 |
| Casey, AR | 1 |
| Schryvers, OI | 1 |
| Sand, PK | 1 |
| Dull, P | 1 |
| Sakaguchi, M | 1 |
| Goto, K | 1 |
| Ichiki, H | 1 |
| Hattori, N | 1 |
| Iizuka, A | 1 |
| Yamamoto, M | 1 |
| Takeda, S | 1 |
| Ishige, A | 1 |
| Aburada, M | 1 |
| Yasuda, M | 1 |
| Yamamoto, T | 1 |
| Armstrong, RB | 1 |
| Luber, KM | 1 |
| Peters, KM | 1 |
| Kripke, C | 1 |
| Corcos, J | 1 |
| Casey, R | 1 |
| Patrick, A | 1 |
| Andreou, C | 1 |
| Miceli, PC | 1 |
| Reiz, JL | 2 |
| Harsanyi, Z | 1 |
| Darke, AC | 2 |
| Salem, P | 1 |
| Hooper, P | 1 |
| Tincello, DG | 1 |
| Richmond, DH | 1 |
| Arango Toro, O | 1 |
| Nohales Taurines, G | 1 |
| Cortadellas Angel, R | 1 |
| Castro Santamaría, R | 1 |
| Gelabert Mas, A | 1 |
| Gupta, SK | 1 |
| Sathyan, G | 1 |
| Versi, E | 1 |
| Appell, R | 1 |
| Mobley, D | 1 |
| Patton, W | 1 |
| Saltzstein, D | 2 |
| Dmochowski, R | 1 |
| Anderson, R | 1 |
| Zinner, N | 1 |
| Lama, D | 1 |
| Roach, M | 1 |
| Miklos, J | 1 |
| Boone, T | 1 |
| Staskin, DR | 1 |
| Crandall, C | 1 |
| Moore, KH | 1 |
| Hay, DM | 1 |
| Imrie, AE | 1 |
| Watson, A | 1 |
| Goldstein, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.[NCT02973659] | 61 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients[NCT00431041] | Phase 4 | 132 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis[NCT01956591] | 1,100 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients - Clinical Effects and Investigating Mechanism of Action[NCT01682603] | Phase 2 | 34 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use[NCT02522936] | Phase 4 | 0 participants (Actual) | Interventional | 2018-08-01 | Withdrawn (stopped due to Due to lack of funding and necessary personnel we determined that the study could not be done.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of subjects reporting incidence of dry mouth as an adverse event (AE) following direct questioning at each patient follow-up visit (NCT00431041)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| Solifenacin | 24 |
| Oxybutynin IR | 53 |
"Subjects were instructed to complete the diary in the 3 day period immediately proceding the visit. Subjects recorded each micturition or instance of passing urine in the toliet.~The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from baseline was calculated as Week 8- Baseline." (NCT00431041)
Timeframe: Baseline and 8 Weeks
| Intervention | Micturitions per day (Mean) | ||
|---|---|---|---|
| Change in micturition frequency at 8 wks(N=52; 40) | Micturition frequency at Baseline (N=68; 64) | Micturition frequency at 8 weeks (N=52; 40) | |
| Oxybutynin IR | -3.1 | 12.5 | 9.0 |
| Solifenacin | -2.3 | 12.4 | 9.9 |
"Subjects were instructed to complete the diary in the 3 day period immediately preceding the visit. Subjects recorded each urgency episode or instance of strong desire to pass urine.~The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from Baseline was calculated as Week 8- Baseline." (NCT00431041)
Timeframe: Baseline and 8 weeks
| Intervention | urgency episodes per day (Mean) | ||
|---|---|---|---|
| Change in urgency episodes at 8 weeks (N=52; 40) | Urgency episodes at Baseline (N= 68; 64) | Urgency episodes at 8 weeks (N=52; 40) | |
| Oxybutynin IR | -3.70 | 6.6 | 2.1 |
| Solifenacin | -2.65 | 6.3 | 3.8 |
"The number of subjects reporting dry mouth at each severity level when dry mouth was reported as an Adverse Event (AE).~Dry mouth severity was categorized as mild (relieved with fluid/hard candy), moderate (dry mouth and throat with no difficulty swallowing solid food/water) & severe (very dry mouth & throat, difficulty swallowing solid food without water)" (NCT00431041)
Timeframe: 8 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Mild | Moderate | Severe | |
| Oxybutynin IR | 16 | 22 | 15 |
| Solifenacin | 18 | 3 | 3 |
(NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | participants (Number) | |
|---|---|---|
| Post-Autonomic dysreflexia | Post-Non Autonomic dysreflexia | |
| Pre-Autonomic Dysreflexia | 5 | 6 |
| Pre-Non Autonomic Dysreflexia | 1 | 22 |
"Bladder compliance is the result of a mathematical calculation of the volume required for a unit rise of pressure measured during a cystometric filling.~Bladder compliance is calculated by dividing the volume change by the change in bladder pressure (mL/cmH2O).~Efficacy:~Net change of the bladder compliance from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL/cmH2O (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 30.6 | 29.0 |
"Efficacy:~Net change of the cystometric bladder capacity (CBC) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 305.9 | 437.6 |
"Efficacy:~Net change of the detrusor pressure (Pdet) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | cmH2O (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 36.1 | 12.9 |
"Efficacy:~Net change of the Incontinence Impact Questionnaire (IIQ-7) from baseline and 12 months.~The IIQ-7 is a 7-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~Total IIQ-7 score ranges = 0 to 21 The total IIQ-7 score can therefore range from 0 to 21 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 11.9 | 5.57 |
"Efficacy:~Net change of the maximum flow rate (Qmax) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL/s (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 4.56 | 3.54 |
"Efficacy:~Net change of the postvoid residual volume (PVR) from baseline and 12 months~Results:~Botulinum toxin A injection have increased postvoid residual urine volume in patients treated for bladder dysfunction.~Treat only patients who are willing and able to initiate catheterization post-treatment, if required, for urinary retention.~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 226.3 | 378.5 |
"Efficacy:~Net change of the quality of life index (QoL-I) from baseline and 12 months. The QoL-I on a 7-point scale ranging from 0 Delighted to 6 Terrible. The QoL-I ranges 0 to 6~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 4.00 | 2.21 |
"Efficacy:~Net change of the UrinaryDdistress Inventory (UDI-6) from baseline and 12 months.~The UDI-6 is a 6-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~The total UDI-6 score can therefore range from 0 to 18 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 10.4 | 7.43 |
"Efficacy:~Net change of the void volume from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 79.6 | 59.2 |
4 reviews available for oxybutynin and Asialia
| Article | Year |
|---|---|
The newer antimuscarinic drugs: bladder control with less dry mouth.
Topics: Benzhydryl Compounds; Controlled Clinical Trials as Topic; Cresols; Delayed-Action Preparations; Dos | 2002 |
Elevating our therapeutic expectations in overactive bladder.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; H | 2004 |
Anticholinergic drugs for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Delayed-Action Preparations; Humans; Mandeli | 2006 |
Tolterodine: a clinical review.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Dose-Response Relationship, Drug; Humans; Ma | 2001 |
12 trials available for oxybutynin and Asialia
| Article | Year |
|---|---|
Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Humans; Hyperhidrosis; Male; Mandelic A | 2015 |
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Topics: Adult; Aged; Aged, 80 and over; Canada; Chi-Square Distribution; Double-Blind Method; Drug Administr | 2010 |
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
Topics: Adolescent; Adult; Aged; Benzilates; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Midd | 2010 |
Transdermal oxybutynin: for overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cresols; Double- | 2003 |
Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
Topics: Adult; Benzhydryl Compounds; Cresols; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; | 2004 |
Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparatio | 2005 |
A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
Topics: Adult; Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Fem | 2006 |
Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Dizziness; Hea | 2007 |
Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
Topics: Administration, Oral; Aged; Area Under Curve; Cholinergic Antagonists; Circadian Rhythm; Cross-Over | 1999 |
Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.
Topics: Chemistry, Pharmaceutical; Cholinergic Antagonists; Delayed-Action Preparations; Dose-Response Relat | 2000 |
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Drug Administ | 2001 |
Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability.
Topics: Double-Blind Method; Female; Humans; Mandelic Acids; Middle Aged; Parasympatholytics; Urinary Bladde | 1990 |
12 other studies available for oxybutynin and Asialia
| Article | Year |
|---|---|
Severe Xerostomia Secondary to Anticholinergic Drug Therapy: Case Report.
Topics: Aged, 80 and over; Cholinergic Antagonists; Female; Humans; Mandelic Acids; Urinary Incontinence; Xe | 2017 |
Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Hyperhidrosis; Male; Mandelic Acids; Mid | 2014 |
Antimuscarinics in Older People: Dry Mouth and Beyond.
Topics: Adrenergic Uptake Inhibitors; Aged; Amitriptyline; Anti-Ulcer Agents; Drug Interactions; Humans; Int | 2016 |
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Midd | 2018 |
[Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis].
Topics: Adult; Drug Evaluation; Female; Follow-Up Studies; Humans; Hyperhidrosis; Male; Mandelic Acids; Midd | 2011 |
Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study.
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Delayed-Action Preparations; Female; Humans | 2002 |
Oxybutynin transdermal (Oxytrol) for overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Benzhydryl Compounds; Cresols; Delayed-Action Prepa | 2003 |
Transdermal oxybutynin (oxytrol) for urinary incontinence.
Topics: Administration, Cutaneous; Cholinergic Antagonists; Drug Administration Schedule; Drug Costs; Humans | 2004 |
Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats.
Topics: Animals; Drugs, Chinese Herbal; Male; Mandelic Acids; Muscle Contraction; Pilocarpine; Plant Extract | 2005 |
The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study.
Topics: Administration, Oral; Female; Humans; Mandelic Acids; Parasympatholytics; Patient Compliance; Pilot | 1997 |
[Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder].
Topics: Adult; Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Urinary Incontinence; Xerostom | 1998 |
Detrol LA and Diropan XL for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Delayed-Action Pre | 2001 |